MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Perlegen Sciences, which develops genetic tests that correlate genetic variation to predisposition to disease and drug response, announced today that it has entered a non-exclusive license agreement with Celera focused on a family of patents that covers methods of genetic analysis central to creating similar diagnostic products. The agreement grants Celera use of this Perlegen intellectual property as well as use of Perlegen’s specific predictive genetic markers on chromosome 9p21 for coronary heart disease, to be included in products marketed by Celera.
